JP2024500562A - Alc1阻害剤およびparpiとの相乗効果 - Google Patents
Alc1阻害剤およびparpiとの相乗効果 Download PDFInfo
- Publication number
- JP2024500562A JP2024500562A JP2023557491A JP2023557491A JP2024500562A JP 2024500562 A JP2024500562 A JP 2024500562A JP 2023557491 A JP2023557491 A JP 2023557491A JP 2023557491 A JP2023557491 A JP 2023557491A JP 2024500562 A JP2024500562 A JP 2024500562A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- optionally substituted
- alc1
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20211730.5 | 2020-12-03 | ||
| EP20211730 | 2020-12-03 | ||
| PCT/EP2021/084089 WO2022117782A1 (en) | 2020-12-03 | 2021-12-03 | Alc1 inhibitors and synergy with parpi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500562A true JP2024500562A (ja) | 2024-01-09 |
| JP2024500562A5 JP2024500562A5 (cg-RX-API-DMAC7.html) | 2024-12-11 |
Family
ID=73792931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557491A Pending JP2024500562A (ja) | 2020-12-03 | 2021-12-03 | Alc1阻害剤およびparpiとの相乗効果 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240033363A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255910A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500562A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230116832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120448A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124235A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021393770A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198803A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023001587A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303333A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006549A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237095A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022117782A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116283828A (zh) * | 2023-02-03 | 2023-06-23 | 广州安岩仁医药科技有限公司 | 一种parp1抑制剂中间体及其制备方法与应用 |
| CN122070131A (zh) | 2023-10-25 | 2026-05-19 | 艾斯巴赫生物有限公司 | 在同源重组缺陷型(hrd)癌症的治疗中使用的作为alc1抑制剂的吡啶并噻吩并嘧啶衍生物 |
| AU2024366320A1 (en) | 2023-10-25 | 2026-04-16 | Eisbach Bio Gmbh | Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs |
| WO2025093706A1 (en) | 2023-10-31 | 2025-05-08 | Eisbach Bio Gmbh | Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan |
| WO2025242703A1 (en) | 2024-05-21 | 2025-11-27 | Eisbach Bio Gmbh | Crystalline forms of an alc1 inhibitor useful in the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US7223556B1 (en) | 1998-10-09 | 2007-05-29 | President And Fellows Of Harvard College | Targeted proteolysis by recruitment to ubiquitin protein ligases |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| AU2001295041A1 (en) | 2000-09-08 | 2002-03-22 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| WO2006010568A2 (de) * | 2004-07-23 | 2006-02-02 | Curacyte Discovery Gmbh | Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung |
| WO2010151664A2 (en) * | 2009-06-26 | 2010-12-29 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| WO2013112706A1 (en) * | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6639497B2 (ja) | 2014-11-10 | 2020-02-05 | ジェネンテック, インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US10154992B2 (en) * | 2016-07-12 | 2018-12-18 | The Regents Of The University Of California | Compounds and methods for treating HIV infection |
-
2021
- 2021-12-01 TW TW110144770A patent/TW202237095A/zh unknown
- 2021-12-02 AR ARP210103350A patent/AR124235A1/es unknown
- 2021-12-03 MX MX2023006549A patent/MX2023006549A/es unknown
- 2021-12-03 US US18/039,740 patent/US20240033363A1/en active Pending
- 2021-12-03 IL IL303333A patent/IL303333A/en unknown
- 2021-12-03 CN CN202180081634.2A patent/CN117120448A/zh active Pending
- 2021-12-03 CA CA3198803A patent/CA3198803A1/en active Pending
- 2021-12-03 WO PCT/EP2021/084089 patent/WO2022117782A1/en not_active Ceased
- 2021-12-03 KR KR1020237020848A patent/KR20230116832A/ko active Pending
- 2021-12-03 EP EP21819146.8A patent/EP4255910A1/en active Pending
- 2021-12-03 JP JP2023557491A patent/JP2024500562A/ja active Pending
- 2021-12-03 AU AU2021393770A patent/AU2021393770A1/en active Pending
-
2023
- 2023-06-01 CL CL2023001587A patent/CL2023001587A1/es unknown
-
2025
- 2025-07-29 US US19/284,162 patent/US20260216344A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| CHEM. HETEROCYCL. COMPD., vol. 42, no. 11, JPN6026006800, 2006, pages 1503 - 1504, ISSN: 0005802337 * |
| J. CHEM. RES., vol. 7, JPN6026006801, 2005, pages 461 - 468, ISSN: 0005802338 * |
| J. COMB, CHEM., vol. 10, JPN6026006802, 2008, pages 313 - 322, ISSN: 0005802339 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3198803A1 (en) | 2022-06-09 |
| TW202237095A (zh) | 2022-10-01 |
| US20240033363A1 (en) | 2024-02-01 |
| KR20230116832A (ko) | 2023-08-04 |
| AU2021393770A1 (en) | 2023-06-22 |
| CN117120448A (zh) | 2023-11-24 |
| US20260216344A1 (en) | 2026-07-30 |
| AR124235A1 (es) | 2023-03-01 |
| WO2022117782A1 (en) | 2022-06-09 |
| EP4255910A1 (en) | 2023-10-11 |
| CL2023001587A1 (es) | 2024-01-19 |
| AU2021393770A9 (en) | 2024-02-08 |
| MX2023006549A (es) | 2023-06-16 |
| IL303333A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240033363A1 (en) | ALC1 Inhibitors and Synergy with PARPi | |
| CN110420327B (zh) | 人ezh2抑制剂及其应用方法 | |
| TWI553005B (zh) | 經取代之酞-1(2h)-酮衍生物 | |
| CN102271681B (zh) | Cxcr7调节剂 | |
| CA3213117A1 (en) | 7-morpholino-l,6-naphthyridin-5-yl derivatives and pharmaceutical compositions thereof useful as dna-pk inhibitor | |
| US10702518B2 (en) | TAF1 inhibitors for the therapy of cancer | |
| KR20230028371A (ko) | 돌연변이 p53 재활성화 화합물에 대한 동반 진단 도구 | |
| JP2013517316A (ja) | 窒素含有へテロアリール誘導体 | |
| PT3004112T (pt) | Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença | |
| JP2025515110A (ja) | Alc1阻害剤の使用およびparpiとの相乗作用 | |
| Jiang et al. | Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia | |
| WO2022079290A2 (en) | Cullin ring ubiquitin ligase compounds and uses thereof | |
| Wang et al. | Diphenylaminothiophen-derived fluorescent ligands targeting mitochondrial DNA G-quadruplexes potentially for triple-negative breast cancer therapy | |
| EP4687894A1 (en) | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer | |
| Ge et al. | Discovery of SY-589, a Highly Potent and Orally Bioavailable Polθ Helicase Inhibitor for the Treatment of HR-Deficient Tumors | |
| CA3068146A1 (en) | Heterochromatin gene repression inhibitors | |
| WO2023203172A1 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| CN117263943A (zh) | 聚(adp核糖)聚合酶选择性抑制剂 | |
| KR102053933B1 (ko) | Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물 | |
| US20250382279A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| US20250368614A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| WO2025104236A1 (en) | Pyrazole compounds as cullin ring ubiquitin ligase compounds | |
| CN120583946A (zh) | 用于yap/tead调节的化合物和方法及其适应症 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241203 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260723 |